0
0
Entebbe, Uganda – The World Health Organization (WHO) has lauded Uganda for executing the fastest rollout of an Ebola vaccine trial during an ongoing outbreak, marking a significant step in combating the deadly virus.
The trial, which commenced on Monday, comes in response to Uganda’s sixth outbreak of the Ebola Sudan strain, a variant for which no approved vaccine currently exists. Unlike the Ebola Zaire virus, which has licensed vaccines, the Sudan strain remains without a definitive immunization solution.
WHO’s Emergencies Director, Mike Ryan, praised the rapid response, emphasizing that the vaccine was developed using a platform similar to that of the effective Ebola Zaire vaccine. “This is a real step forward,” he stated, noting that while the vaccine has demonstrated safety in preliminary trials, continued monitoring of its efficacy remains essential.
Unprecedented Speed in Vaccine Deployment
Ryan highlighted that this marks the fastest vaccine rollout he has ever witnessed during an active epidemic. He also underscored the remarkable efficiency of Ugandan scientists in sequencing the virus within 24 hours, a feat that allowed for swift global data sharing.
Currently, approximately 2,400 vaccine doses are available in Uganda. These vaccines are being administered specifically to individuals who have had contact with confirmed cases, aiming to curb transmission and prevent severe illness. Ryan reassured the public that this targeted vaccination strategy minimizes risks to the broader population.
Global Health Landscape and WHO Partnerships
Discussing global health dynamics, Ryan acknowledged shifts in international collaboration, particularly in light of the United States’ withdrawal from WHO. Despite the loss of U.S. contributions, he highlighted Uganda’s strengthened medical and logistical capabilities as a testament to global health advancements over recent decades.
Disclaimer
This article is based on information available as of 2025. The Ebola Sudan vaccine trial is ongoing, and its safety and efficacy continue to be evaluated. Readers should refer to official health sources for the latest updates and guidelines.
© 2025 AFP
